Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Early Intervention an Unmet Need in Diabetic Macular Edema
A Delphi study presented at the ARVO meeting highlighted a major gap in diabetic macular edema (DME) care: 60% of patients remain untreated one year after diagnosis. Experts reached consensus that early, non‑invasive treatment could stabilize vision and curb inflammation before functional loss occurs. The panel identified early‑intervention goals, preferred treatment thresholds, and called for better adherence, safety, and combination‑therapy options. These findings underscore the urgency for new therapeutic approaches targeting the early stages of DME.
MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage
The White House’s most‑favored‑nation (MFN) drug pricing framework projects roughly $600 billion in savings over the next decade, tying U.S. prices to the second‑lowest net price among eight high‑income reference countries. The plan distinguishes prospective launches, which could slash net prices...
AI Tools Could Restore ‘Joy of Practice,’ Lower Physician Burnout
At Digestive Disease Week, Microsoft’s chief clinical product lead David Ting warned that more than half of U.S. physicians exhibit burnout, a condition tied to a 20% increase in medical errors. He argued that generative‑AI agents—such as Google Gemini, Microsoft...
What The Data Actually Shows About Medical Malpractice Across America
Kitchel Law’s analysis of malpractice reports from 2021‑2025 reveals stark geographic disparities. New Mexico leads with 131 reports per 1,000 practitioners, while New York generates the most total filings (5,932) but ranks lower on a per‑physician basis. California, despite its...
Antibiotic Resistance Genes Found in Newborns’ Stool
Researchers at Aristotle University of Thessaloniki analyzed 105 meconium samples from NICU infants and found a median of eight antibiotic‑resistance genes (ARGs) within the first 72 hours of life. Nearly all samples carried quinolone‑resistance genes, while 21% harbored carbapenem‑resistance determinants...
Patient Autonomy in Psychiatry and the Ethics of Care
Psychiatrist Wonyun Lee describes how U.S. mental‑health law prioritizes patient autonomy over beneficence, leaving individuals like K—who cycles through emergency rooms, shelters, and brief hospitalizations—without adequate care. The article contrasts this approach with Korean practice, where physicians intervene more readily...
Peptides Boost Hormones, Yet Trigger Serious Metabolic Side Effects
People mistakenly believe peptides are only good. Peptides can be bad, too. They can cause adverse effects. Some dangerous. I did a peptide experiment and measured its effects in my body. The results are complicated. I tried a peptide called CJC-1295....
What’s New in Clinical Trial Innovation
The FDA’s Center for Clinical Trial Innovation (C3TI) publishes a newsletter that highlights new developments, opportunities, and initiatives in clinical‑trial innovation. Readers can subscribe via a public.govdelivery.com form to receive updates directly in their inbox. The site also provides free...
General Devices’ User Spotlight: Inside OB Alert Success at Mercy Medical Center: Faster Response, Better Patient Care
Mercy Medical Center in Springfield, Massachusetts has expanded its use of General Devices’ GD Solution Suite, including e-Bridge and CAREPoint, to replace unreliable radio communications. EMS Coordinator Renee Rochette, a veteran paramedic, reports the platform now handles about 30 e‑Bridge...
FDA Launches Elsa 4.0, Touts Benefits For Employees
The FDA unveiled Elsa 4.0, an upgraded internal large‑language‑model platform, on May 4. The new version enables employees to build custom AI agents, auto‑generate regulatory documents, run data analyses, and conduct secure internet searches. By embedding generative AI directly into product‑review...
Treating Cancer Based on Mutation Alone Does Not Improve Survival
A large Australian study of 3,383 advanced‑cancer patients found that targeted therapies approved for a specific mutation within the same tumor type improved overall survival by roughly 40%, while using a drug solely because of a shared mutation across different...
Metabolic Stability in Peptide Therapeutics
Peptide therapeutics are gaining traction but remain hampered by poor metabolic stability, limited permeability, and rapid clearance. The article outlines four primary metabolic pathways—hydrolysis, oxidation, reduction, and conjugation—and examines the hurdles of oral delivery, in‑vitro tools, and experimental workflows used...
How Worried Should You Be About Hantavirus?
An outbreak of hantavirus was reported aboard the MV Hondius cruise ship, which left Argentina on April 1 with about 150 passengers and crew. Cases emerged in early May, prompting the World Health Organization, the U.S. CDC, and Cape Verde health officials...
AstraZeneca’s Camizestrant Hit by FDA Advisory Committee Vote While Truqap Moves Ahead
FDA’s Oncologic Drugs Advisory Committee issued a split verdict on AstraZeneca’s oncology pipeline this week. The committee voted 3‑to‑6 against the benefit‑risk profile of camizestrant combined with a CDK4/6 inhibitor for ESR1‑mutated advanced breast cancer, despite a 56% progression‑free survival...
OECD Blog Item Explores Why Biotech Start-Ups Lag in Europe
The OECD’s May 6 blog highlights that Europe continues to fall behind the United States and Asia in biotech start‑up formation, patenting, and venture‑capital funding. It points to the European Commission’s December 2025 Biotech Act, which introduces regulatory sandboxes, pre‑submission consultations, a...
Turning Oncology Frustrations Into Quality Improvement Solutions: Eileen Ehret, BS
Eileen Ehret, vice‑president of regulatory and compliance at Navista, spoke at the 2026 Community Oncology Conference about a Care Fresno case study that uncovered a regimen‑scheduling error in its electronic health record. The team built a digital macro checklist embedded directly...
Bayer Sees Opportunity With $300M Acquisition of Eye Drug Biotech
Bayer announced a $300 million upfront acquisition of Perfuse Therapeutics, a clinical‑stage biotech developing PER‑001, an endothelin‑receptor blocker delivered via a six‑month intravitreal implant. Phase 2 trials showed significant vision improvement in glaucoma and diabetic retinopathy, positioning the drug as a potential...
Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial
Zentalis Pharmaceuticals announced the first patient dosing in the Phase III Aspenova trial of Azenosertib, an oral WEE1 inhibitor for Cyclin E1‑positive, platinum‑resistant ovarian cancer. The study is run with the GOG Foundation, the European Network of Gynecological Oncology Trials (EN‑GOT), and...
HOPE Supports Tailored Approach to BP After Stroke Thrombectomy
The HOPE trial, presented at the European Stroke Organisation Conference 2026, tested a reperfusion‑guided blood‑pressure strategy after endovascular thrombectomy for acute ischemic stroke. Patients whose post‑procedure mTICI score was 2b were targeted to a systolic BP of 140‑160 mm Hg, while those...
Brolucizumab Superior in Preserving Visual Acuity in Proliferative Diabetic Retinopathy
A phase‑3 CONDOR trial of 689 adults with proliferative diabetic retinopathy (PDR) showed that intravitreal brolucizumab outperformed panretinal laser photocoagulation (PRP) in preserving visual acuity over 54 weeks. The brolucizumab arm gained a mean BCVA change of +0.2 letters versus...
Ben Salter, SafeRide Health
SafeRide Health, a leading non‑emergency medical transportation (NEMT) provider for Medicaid and Medicare Advantage plans, showcased its end‑to‑end ride‑scheduling platform in a recent demo. Chief Product Officer Ben Salter walked through the system’s interface for call‑center agents and members, illustrating...
Why, After Lumbar Correction and Cervical Alignment, Does the Cervical Spine Drift Back Into Malalignment Two Years Later?
A retrospective cohort of 99 patients undergoing lumbar pedicle subtraction osteotomy (PSO) showed dramatic immediate improvements in cervical alignment, including reductions in cSVA, cervical lordosis, and T1 slope. The magnitude of these early changes was linked to higher pre‑operative sagittal...
Honoring Nurses: Compassion, Skill, and Everyday Dedication
Today we give a special shoutout to the nurses who show up every day with compassion, skill, and dedication. You care for our families, strengthen our communities, and make a lasting difference across our state. Thank you for all that you...
What Hidden Constraints Shape Clinical Decisions?
Timothy Lesaca introduces “invisible triage,” a pre‑conscious filter that shapes which clinical options ever reach a physician’s awareness. He argues that systemic forces—time pressure, EHR templates, protocols, and incentives—narrow the decision space before reasoning begins, often hiding critical diagnoses. The...
MAHA Voters Support Lower Health Care Costs Above Vaccine Safety and Limitation of Pesticides, Poll Finds
A new KFF poll of over 1,300 MAHA supporters shows that 42% rank lowering health‑care costs, including prescription drugs, as their top priority, far ahead of concerns about food additives (21%) and vaccine safety (10%). The preference cuts across party...
How Specialty Drug Commercialization Differs in Canada From the US
Jessica Lovett, VP of Commercial Strategy at Innomar Strategies, outlined a 24‑month planning horizon for specialty drug launches in Canada, emphasizing early coordination with Health Canada. The roadmap moves from pre‑development regulatory and import considerations to a 12‑18‑month development and...
Clinical Trials Day
Clinical Trials Day on May 20 commemorates James Lind’s 1747 scurvy experiment, widely regarded as the first randomized clinical trial. The observance highlights the enduring role of trials in generating the safety and efficacy data that underpin FDA drug approvals. FDA’s...
Ypsilanti, Michigan Council Approved Unarmed Crisis Response Program
The Ypsilanti City Council approved a resolution to launch a city‑run “community responder” program that sends unarmed social workers and mental‑health specialists to certain emergency calls. The initiative targets behavioral health crises, substance‑use incidents and homelessness, while police remain on...
Developing a Learning Health System Approach to Sepsis
Stephanie Taylor, former Wake Forest chief, is now leading a sepsis learning health system at the University of Michigan. Her team created the STAR program, a tele‑health and navigator‑led model for high‑risk sepsis survivors, and is extending that framework into an...
BsUFA IV: Fiscal Years 2028-2032
The FDA announced the kickoff of the fourth Biosimilar User Fee Act (BsUFA IV) reauthorization, covering fiscal years 2028‑2032. A public meeting was held on December 3, 2025 to launch the process, following the 2022 law that reauthorized BsUFA II. BsUFA III expires in September 2027,...
In a First, Scientists Are Rewinding Human Cells Back to a ‘Youthful’ State. Is This the Dawn of Immortality?
Scientists are advancing partial cellular reprogramming to reverse age‑related decline while preserving cell identity. YouthBio Therapeutics is preparing a first‑in‑human trial of its brain‑targeted YB002 program for Alzheimer’s after receiving FDA feedback. Parallel efforts such as Life Biosciences’ ER‑100 aim...
Study Finds Patients Willing to Use Lower-Cost Treatments to Keep Weight Off, Allowing More Access to GLP-1s
A University of Michigan College of Pharmacy study of more than 700 U.S. adults with obesity found that over 80% support insurer strategies that cover full‑dose GLP‑1 injections during the active weight‑loss phase and then transition patients to lower‑cost maintenance...
WEDI Launches Interoperability Testing Directory
WEDI has launched a free, web‑based directory that matches payers, providers, and vendors seeking partners to test the CMS‑0057‑F APIs required for the January 1 2027 interoperability deadline. The service collects basic information—organization name, API versions, testing windows—and makes it publicly searchable,...
PRP Therapy Protocols Lack Expert Consensus
Platelet‑rich plasma (PRP) therapy lacks a unified peri‑procedural protocol, with leading experts disagreeing on NSAID washout periods, supplement restrictions, cryotherapy, and rehabilitation timing. The article highlights that ten top clinicians offered divergent recommendations on pre‑procedure NSAID use, corticosteroid washout, and...
The Round Up: Oh Dear, Palantir Is Doing Very Well Financially...
During local election week, mainstream media and social‑media algorithms prioritize campaign noise, pushing substantive issues like NHS policy to the background. The author argues that journalists are under‑reporting politicians' relationships with private companies and the impact of their decisions on...
Talkspace Expands U.S. Navy Mental Health Partnership to 13 Bases
Talkspace is extending its mental‑health partnership with the U.S. Navy to 13 installations, adding the Talkspace Go self‑paced app to the benefits of more than 40,000 sailors and their families. The service provides virtual therapy for a wide range of...
A Candid Look at Antifungal Treatment Durations
Current IDSA guidelines mandate at least 14 days of antifungal therapy after blood‑culture clearance for invasive candidiasis, a rule rooted in a three‑decade‑old trial. Recent pilot and retrospective studies suggest that a 5‑10‑day course can achieve comparable cure rates and...
Policy Sclerosis Is Ravaging the NHS and Whitehall
The Health Foundation reports that UK healthy life expectancy (HLE) has slipped to just under 61 years, dropping the country to 20th place among 21 high‑income nations. The decline follows a decade‑long fall in HLE, contrasting with gains elsewhere. The...
Therapy First, Meds When Needed: Balanced Mental Health Care
Mental Health Month reminder #3: Not everyone with a psychiatric condition needs medication. I'm extremely conservative especially when it comes to kids. Addressing stressors, both physiologic and environmental, & therapy are critical to supporting mental health. But for many, medication is also...
Young‑Adult Work Activity May Shield Against Dementia
Physical activity across the life course and neural biomarkers 💡"PA done as part of one's job or schooling during young adulthood, such as standing and walking, may be protective against dementia later in life." https://t.co/tGarY3gUA2
FDA Approves Fruit-Flavored Vapes As Controversy Mounts For Makary
The FDA authorized marketing of fruit‑flavored e‑cigarette products on May 5, marking the first such approval in U.S. history. The move follows reports that President Donald Trump pressured FDA Commissioner Marty Makary to green‑light the flavors, a promise he made during...
Parents Refusing Newborn Vitamin K Cause Fatal Bleeding
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth https://t.co/M8iRheTRCj
I’m Sorry, but I Can’t Help with That.
None of the Covid shot batches saved any lives. They did take a lot of lives. And nobody died of Covid. They died of comorbidities or hospital negligence.
Rula Report Finds 52% of Americans Still Skipping Mental‑Health Care as Anxiety Rises 10%
Rula released its 2026 State of Mental Health Report, revealing that more than half of U.S. adults have never accessed therapy despite a surge in anxiety and depression. The data underscores a widening gap between growing awareness and actual service...
Heroic Psilocybin Dose Dramatically Rewires Brain Connectivity
“Scientists gave people a “heroic” dose of psilocybin and then looked at their brain. Here’s what happened” https://t.co/M9FjCRGNNq
AI May Outdiagnose Doctors, but Context Matters
A recent Science paper suggested doctors are now outstripped at diagnosis patients by AI - but there's more than meets the eye. My latest for @bmj_latest https://t.co/yE3r2q8U7U
80+ Therapeutic Peptides Approved Across Major Disease Areas
Did you know... over 80 therapeutic peptides have been approved to treat a wide array of diseases, ranging from infectious diseases, cardiovascular, dysmetabolic diseases, and cancer: https://t.co/kW4zgAcmE3
From EHR Adoption to Value‑Driven Healthcare IT
Healthcare IT has come a long way. Todd Richardson reflects on the journey—from getting EHRs in place and earning a seat at the table, to today’s focus on driving value, lowering costs, and navigating consolidation. 🔗https://t.co/ajvQcsSgal @HCTecTN #healthcarelabor #HITSM https://t.co/oYdj2MduXb
AI Proven in Kenya, Yet Underused Stateside for Health Equity
A reminder that AI can be used to reduce health inequities. Technology not being used in the US except for a few health systems, but shown to work well in Kenya @JAMACardio https://t.co/tFbbOAeKTs
Accurate Data Is the Foundation of Patient Verification
Your patient verification is only as strong as your data. If records are wrong, everything breaks. See why data quality comes first.👇 https://t.co/rVWbQPYm71 @melissadata #PatientVerification #HITSM